Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus TESTOSTERONE ENANTHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus TESTOSTERONE ENANTHATE.
HALOTESTIN vs TESTOSTERONE ENANTHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Testosterone enanthate is a prodrug of testosterone, which binds to and activates androgen receptors (AR), modulating gene expression and exerting anabolic and androgenic effects. It also exhibits some affinity for estrogen receptors via aromatization.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
50-400 mg intramuscularly every 2-4 weeks
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Terminal elimination half-life is approximately 4-5 days (range 3.5-7 days) after intramuscular injection due to slow absorption from the oily depot; supports weekly to biweekly dosing intervals.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Primarily renal (90% as glucuronide and sulfate conjugates, 6% unchanged) and biliary/fecal (10%).
Category C
Category D/X
Androgen
Androgen